scholarly journals A Clear Cell Renal Cell Carcinoma Inhibiting the Response to Intravitreal Antivascular Endothelial Growth Factor Therapy in Wet Age-Related Macular Disease

2012 ◽  
Vol 3 (3) ◽  
pp. 443-451 ◽  
Author(s):  
Manuel S. Falcão ◽  
João Vinagre ◽  
Paula Soares ◽  
JoséManuel Lopes ◽  
Elisete Brandão ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Growth Factor ◽  
Clear Cell ◽  
Macular Disease ◽  
Cell Renal Cell Carcinoma ◽  
Age Related ◽  
Antivascular Endothelial Growth Factor ◽  
Factor Therapy ◽  
Growth Factor Therapy ◽  
Endothelial Growth Factor

scholarly journals Ten-year outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration

Eye ◽  
2020 ◽  
Vol 34 (10) ◽  
pp. 1888-1896 ◽  
Author(s):  
Shruti Chandra ◽  
Cristina Arpa ◽  
Deepthy Menon ◽  
Hagar Khalid ◽  
Robin Hamilton ◽  
...  
Keyword(s):  
Growth Factor ◽  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Age Related ◽  
Antivascular Endothelial Growth Factor ◽  
Factor Therapy ◽  
Growth Factor Therapy ◽  
Endothelial Growth Factor

Office Examinations–Directed Treatment Paradigms Reduce Travel Burden, Decrease Treatment Cost, and Improve Quality-Adjusted Life-Years for Patients With Exudative Age-Related Macular Degeneration Undergoing Antivascular Endothelial Growth Factor Therapy

2020 ◽  
Vol 4 (6) ◽  
pp. 472-478
Author(s):  
Geoffrey G. Emerson ◽  
John T. Thompson ◽  
Loi V. Vo ◽  
Robert W.H. Mason ◽  
Gregory D. Lee ◽  
...  
Keyword(s):  
Growth Factor ◽  
Quality Adjusted Life Year ◽  
Age Related Macular Degeneration ◽  
Age Related ◽  
The Us ◽  
Antivascular Endothelial Growth Factor ◽  
Factor Therapy ◽  
Growth Factor Therapy ◽  
Endothelial Growth Factor ◽  
Quality Adjusted Life

Purpose: In the United States, most intravitreal injections are performed the same day as an office examinations; however, federal agencies and insurance payers suggest these same-day examinations charges are overused and have recommended scrutiny. In this study, we estimate the cost vs benefit to society of same-day office examinations during intravitreal injections for wet age-related macular degeneration (wAMD). Methods: An Excel spreadsheet was used to model different antivascular endothelial growth factor treatment scenarios for wAMD, including automatic treatment, injection series' treat and extend (T&E), and as-needed treatment, with increasing same-day examinations in the order listed. Treatment parameters were estimated using US population statistics, published literature, and Centers for Medicare & Medicaid Services, provider utilization data. Costs and benefits were compared for the 4 treatment scenarios. Results: Although yearly examinations and optical coherence tomography costs were higher for injection series, T&E, and as-needed protocols compared with automatic treatment, our model predicts reduced yearly injection and travel costs for those same treatment scenarios also, saving $2.9 billion (injection series), $7.2 billion (T&E), and $6.1 billion (as-needed) annually for the US population. Same-day injections accounted for 21%, 8%, and 9% of the savings, respectively, because of reduced travel burden. Furthermore, early detection of wAMD in the fellow eye during office examinations allows for a 1.8, 2.1, and 2.5 quality-adjusted life-year benefit, respectively. Conclusions: Office examinations–directed antivascular endothelial growth factor therapy for wAMD reduces travel and treatment expenses and improves screening of the fellow eye, resulting in robust cost savings and quality-adjusted life-year benefit for the US population.

Sign in / Sign up

Export Citation Format

Share Document